The medical cannabis division of the company, Tilray Medical, has now completed the export and sale of its first cannabis products to Malta.
Patients in Malta will now have access to Tilray’s EU-GMP, pharmaceutical grade medical cannabis products. The products are now accessible through pharmacies across the country.
Medical cannabis has been legal in Malta since 2018 following the enactment of the Production of Cannabis for Medicinal and Research Purposes Act and amendments to the Drug Dependence Act.
Patients are able to obtain medical cannabis prescriptions along with a medical cannabis card – issued by Malta’s Superintendent of Public Health – through family doctors.
Read more: Tilray sees net revenue increase to $513m from last year
Tilray’s CSO and head of international business, Denise Faltischek, commented: “As demand for cannabis continues to grow across Europe, we’re incredibly proud to partner with established and reliable distribution partners to supply new markets with high-quality medical cannabis which patients can rely on.”
The company – the only one to operate two state-of-the-art GMP-certified cannabis cultivation facilities in Europe, located in Cantanhede, Portugal, and Neumunster, Germany – was the first to successfully import medical cannabis products into Europe in 2016.
Following an announcement in January of a new parent name, Tilray Brands, Inc., to reflect its transition from a Canadian LP to a global consumer packaged goods company, Tilray consolidated its global medical offering into Tilray Medical in February.
The company – which a number one leading position in Germany having a 20 per cent market share – has stated the global medical platform will give patients in North America access to Tilray’s brands and product choices globally. This includes Tilray, Aphria, Broken Coast, and Symbios, with Tilray Medical planning to expand its offering to patients worldwide.
At the time of the consolidation, Faltischek stated: “Tilray is the global leader in the advancement of cannabinoid-based medicine, with a focus on providing research-backed medical cannabis products to physicians, pharmacies and patients.
Read more: Tilray sees ongoing progress across Europe
“By unifying the global medical divisions of Tilray and Aphria under a cohesive strategy and mission, Tilray Medical emerges as the premier global supplier of a portfolio of high-quality, effective medical cannabis brands and products for patients in need around the world.”
Recent developments also saw the global cannabis company named as the supplier cannabis products for Luxembourg’s medical cannabis programme by the Luxembourg Ministry of Health.
The company has previously stated that Tilray’s growth potential in the European Union represents a $1bn (~£0.74bn) opportunity.
[activecampaign form=31]
